Drug intelligence / Profile preview

SAL0127

Development stage: Preclinical
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules

Overview

SAL0127 is a small molecule inhibitor of Coagulation factor XIa (FXIa) currently in preclinical development by Shenzhen Salubris Pharmaceuticals. It is being investigated for the prevention and treatment of thrombotic diseases. By selectively inhibiting FXIa, SAL0127 aims to target the intrinsic pathway of the coagulation cascade, which is hypothesized to reduce the risk of thrombosis while maintaining better hemostatic control and a lower risk of clinically significant bleeding compared to traditional anticoagulants that target the common pathway.

Targets

Factor XIa

Beyond the preview

Go deeper on SAL0127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL0127.

Explore the full profile